Videndum Posts Steeper Loss in 2025 Amid Revenue Decline, Completes Major Refinancing

Videndum’s 2025 numbers: revenue down, losses widen, and a big reset of the balance sheet

Videndum has reported a tougher 2025 but finished the period by pulling off a sizeable refinancing to steady the ship. Revenue from continuing operations fell to £228.3 million and profitability shrank, yet a March 2026 equity raise and lender support have slashed pro forma net debt and eased near-term pressure. Here’s what stood out – and what it means for investors.

Headline figures investors should know

Measure (continuing unless stated)	2025	2024
Revenue	£228.3m	£280.7m
Adjusted EBITDA (earnings before interest, tax, depreciation and amortisation)	£9.0m	£20.1m
Adjusted loss before tax	£(31.5)m	£(25.0)m
Adjusted operating cash flow	£5.3m	£16.6m
Free cash flow	£(23.6)m	£4.3m
Net debt (pre-refinancing, incl. leases)	£142.3m	£133.0m
Statutory operating loss (total operations)	£(53.9)m	£(84.5)m
Statutory loss before tax (total operations)	£(66.8)m	£(103.4)m
Loss per share (total operations)	(68.1)p	(155.8)p

Management notes the rate of revenue decline improved through the year – H1 was down 25%, H2 down 8% (excluding 2024 Olympics revenue), and Q4 just 3% lower year-on-year. Cost savings of about £15 million helped, but lower volumes and higher finance costs still drove deeper losses.

Refinancing: the clear bright spot

On 30 March 2026 Videndum completed a comprehensive refinancing:

• £85.0 million equity raise (net £78.9 million) at 270 pence per new share, upsized due to demand.
• £23.0 million of previous RCF debt equitised into new shares.
• £15.8 million of RCF debt written off by lenders.
• New facilities totalling £60.0 million: £31.5 million 3-year Term Loan A, £13.5 million 2-year Term Loan B, and a £15.0 million 3-year Super Senior RCF.

After fees, this reduces 31 December 2025 pro forma net debt by £111.7 million to £30.6 million, including £25.2 million of finance leases. That is a dramatic deleveraging and, in my view, the single most important development for equity holders. There’s a £5.0 million minimum liquidity covenant, while leverage and interest cover tests only come back from 31 March 2028 – giving time to trade out of the downturn.

One caveat: the company incurred over £25 million of refinancing-related costs across the last fifteen months. Management says no further costs are anticipated.

What drove the 2025 decline?

Videndum sells premium kit and software to content creators: camera supports, lighting, transmission, robotics, audio and the like. 2025 was knocked by market caution, particularly in the US after tariffs announced on 2 April 2025. H2 tariff reductions helped, but uncertainty lingered. The Group has filed to recover tariff costs following a SCOTUS ruling that the tariffs were unlawful, although no recovery is expected in FY 2026.

Operationally, the Group did a lot of self-help: £15 million of savings delivered in 2025 (exit run-rate c.£19 million) and a further c.£8 million expected in 2026 from current projects. Inventory was cut by about £15 million (20%), cash beneficial and slightly ahead of the revenue decline.

Divisional colour: where it hurt and where it held up

• VMS (Media Solutions): revenue £108.5 million, down 18%; adjusted EBITDA £11.2 million (down £1.6 million). Heavy restructuring delivered c.£9.0 million of savings. The Manfrotto ONE system launched to strong feedback, but full production only lands in 2026.
• VPS (Production Solutions): revenue £72.7 million, down 20% (or down 12% excluding the 2024 Olympics boost). Adjusted EBITDA dropped to £1.6 million. Savings of about £3.5 million helped but adverse operating leverage dominated.
• VCS (Creative Solutions): revenue £47.1 million, down 18%. Despite this, adjusted EBITDA rose to £7.5 million, helped by £3.5 million higher adjusted other income and restructuring savings. Statutory operating profit improved to £3.3 million.

Corporate costs also fell year-on-year thanks to lower consultancy and audit fees and restructuring benefits.

Portfolio moves and product pipeline

• Sold the Amimon Israeli business in April 2025 while retaining intellectual property within Teradek; profit on disposal from discontinued operations £4.8 million.
• Exited the consumer end of the market by selling the JOBY brand in September 2025 for £5.2 million; profit on disposal £3.9 million (offset by post-disposal inventory losses included in adjusting items).
• Launched 22 new product lines in 2025 (seven in 2024, six in 2023), including the ‘new to world’ Manfrotto ONE stability system. AI-enabled launches included Vinten VEGA (subject tracking) and Autoscript Voice (speech recognition).

Strategically, that’s a clear tilt toward professional markets and higher-value innovation – sensible, given intense competition in consumer gear.

Cash, debt and liquidity

Free cash outflow was £23.6 million, reflecting interest of £12.2 million, restructuring spend of £9.6 million and debt amendment/refinancing costs of £9.5 million. Year-end liquidity was £14.2 million, made up of £11.0 million net cash and £3.2 million undrawn RCF. Net debt increased by £9.3 million to £142.3 million before the March 2026 deleveraging.

Adjusting items totalled £38.5 million, mainly non-cash impairments (£26.1 million, including acquired intangibles) and restructuring. Importantly, the balance sheet is much cleaner now, with intangible write-downs taken and non-core assets exited.

Outlook and targets

The Board expects good revenue growth in FY 2026, supported by the 2025 and 2026 product introductions. Medium term, Videndum is aiming for revenue over £350 million and a mid-teens adjusted EBITDA margin, underpinned by operational efficiencies, cost reduction and new product contribution. The dividend remains paused, with the Board intending to resume a “progressive and sustainable” payout when appropriate.

Going concern: read the small print

The auditors signed with a material uncertainty in relation to going concern. Management’s stress tests still show positive liquidity within the 12‑month assessment and “foreseeable future”. However, if trading stayed at stressed levels beyond that period, the Group may need to consider asset sales, restructuring or broader reorganisation. That is not a base case, but it is flagged for completeness.

My take: what this means and why it matters

• Deleveraging is the turning point. Cutting pro forma net debt to £30.6 million (including £25.2 million of leases) transforms financial risk and buys time for the product cycle to work. That materially improves the equity story.
• Execution now moves centre stage. Cost savings are coming through, but FY 2026 depends on converting the pipeline – notably Manfrotto ONE scaling production – and stabilising US demand post‑tariffs.
• Cash discipline remains critical. 2025’s outflow was driven by interest and one‑off costs; with refinancing complete and inventories lower, cash conversion should improve, but investors will want to see that in reported numbers.
• Targets are ambitious. Revenue “in excess of £350 million” and a mid‑teens EBITDA margin are attractive, yet they require a sustained market recovery plus delivery from new products and Asia expansion. Sensible, but not guaranteed.
• Risk factors haven’t vanished. The going‑concern material uncertainty sits in the background, and market volatility (including geopolitical events) could knock demand. No dividend until the balance sheet and cash flows are stronger.

What to watch in 2026

• Top-line growth versus the “good revenue growth” guidance, and whether Q1/Q2 momentum matches the late‑2025 stabilisation (Q4 down 3% year‑on‑year).
• Adjusted EBITDA progression as cost savings annualise and volumes recover.
• Cash flow and liquidity headroom versus the £5.0 million minimum covenant.
• Uptake of new launches, especially Manfrotto ONE, and continued AI-enabled features in broadcast and creative lines.
• Any update on tariff cost recovery claims – management does not expect recovery in FY 2026.

Bottom line

Operationally, 2025 was another slog. Financially, the March 2026 refinancing is a reset that meaningfully reduces risk and gives Videndum breathing space. If management converts the bulging product pipeline and demand normalises, there is credible upside to margins and cash. Until then, this remains a recovery story: better funded, still execution‑dependent.